Victory Capital Management Inc. cut its stake in BioAtla, Inc. (NASDAQ:BCAB) by 4.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,706 shares of the company’s stock after selling 524 shares during the quarter. Victory Capital Management Inc.’s holdings in BioAtla were worth $454,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Citigroup Inc. raised its stake in shares of BioAtla by 511.0% in the first quarter. Citigroup Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 925 shares during the period. Royal Bank of Canada bought a new position in BioAtla during the 1st quarter valued at about $55,000. UBS Group AG raised its position in BioAtla by 399.6% in the 1st quarter. UBS Group AG now owns 2,528 shares of the company’s stock worth $129,000 after purchasing an additional 2,022 shares during the period. New York State Common Retirement Fund lifted its stake in BioAtla by 64.6% in the second quarter. New York State Common Retirement Fund now owns 11,191 shares of the company’s stock worth $474,000 after purchasing an additional 4,391 shares during the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of BioAtla in the first quarter worth approximately $224,000. 62.62% of the stock is owned by institutional investors.
Shares of BCAB stock opened at $34.55 on Friday. BioAtla, Inc. has a twelve month low of $27.15 and a twelve month high of $76.63. The stock has a fifty day simple moving average of $40.02 and a two-hundred day simple moving average of $45.47.
Several equities analysts have commented on the company. Roth Capital assumed coverage on BioAtla in a research report on Monday, June 28th. They issued a “buy” rating and a $75.00 price objective on the stock. Zacks Investment Research downgraded shares of BioAtla from a “hold” rating to a “sell” rating in a research note on Wednesday, August 18th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $65.20.
In other BioAtla news, CEO Jay M. Phd Short sold 4,533 shares of the firm’s stock in a transaction that occurred on Tuesday, August 24th. The shares were sold at an average price of $41.60, for a total value of $188,572.80. Following the completion of the sale, the chief executive officer now directly owns 1,441,508 shares in the company, valued at $59,966,732.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Scott Andrew Smith sold 33,244 shares of the stock in a transaction on Thursday, August 26th. The shares were sold at an average price of $40.16, for a total value of $1,335,079.04. Following the sale, the president now owns 368,568 shares of the company’s stock, valued at approximately $14,801,690.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 647,719 shares of company stock worth $25,677,381. Insiders own 35.50% of the company’s stock.
BioAtla, Inc, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.
Recommended Story: History of the Euro STOXX 50 Index
Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB).
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.